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PIEN XT (Jan 2013-September 2014) and SAPIEN 3 (October 2014-
March 2015). All patients presented severe aortic stenosis who were
refused for conventional surgery. Procedure success, clinical out-
comes and peri-procedural complications were prospectively assessed
according to the Valve Academic Research Consortium (VARC)-2
criteria.
RESULTS N¼142 consecutive patients who underwent TAVR using
SAPIEN device were included in the study (n¼76 SAPIEN XT and n¼66
SAPIEN 3). There was no difference between groups regarding age,
Euroscore, gender, previous medical history and left ventricle ejection
fraction. However, SAPIEN 3 patients had a higher prevalence of pe-
ripheral arterial disease (65.2 vs. 36.8%, p¼0.001) and ilio-femoral axis
calciﬁcations on scanner (47.9 vs; 26.5 %, p¼0.008) than the others.
Moreover, SAPIEN 3 patients had a smaller aortic valve area than
SAPIEN-XT subjects (0.670.9 vs 0.76  0.14 cm2/m2, p¼0.007), yet
there was no signiﬁcant difference in aortic annulus diameter (254.5
vs 23.82 mm, p¼ns). TAVR was performed through transfemoral
access in 96% in both groups. Device implantation success rate was
higher (100% vs. 90%, p¼0.002) in the SAPIEN 3 than in the SAPIEN-
XT group .The prevalence of moderate to severe paravalvular leak was
lower in SAPIEN 3 than in SAPIEN-XT patients (0% vs 9.2%, p¼0.01).
We observed fewer hemorrhagic events in the SAPIEN 3 group than in
the other, as assessed by the lower incidence of life-
threatening þmajor bleeding events (0% vs 9.2%, p¼0.01). There was
no difference regarding the 30-days rate of MACCE (major adverse
cardiovascular & cerebrovascular events) between patients, including
no difference in terms of death (3% vs. 5%), stroke (3% vs. 2.6%) and
major vascular complications (6% vs. 13.1%). Finally, the rate of per-
manent pacemaker implantation were comparable in both groups
(10.6 vs. 14.5%, p¼0.49).
CONCLUSIONS The use Edwards SAPIEN 3 allows TAVR in patients
with more severe peripheral artery disease. Moreover, this device
provides excellent short-term outcome and lower rates of para-
valvular regurgitations compared to the previous generation SAPIEN-
XT valve.
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BACKGROUND Prospective randomized trials have demonstrated
that transcatheter aortic valve replacement (TAVR) is an effective
alternative to surgical aortic valve replacement (SAVR) for patients
with severe aortic stenosis at increased surgical risk, but reasons why
left ventricular (LV) mass regresses more rapidly and to a greater
extent after SAVR than TAVR despite a higher AV gradient after SAVR
is unknown. We sought to determine why LV mass regression is
greater after SAVR.
METHODS Baseline and serial echocardiography studies of patients
randomized to SAVR with a bioprosthetic valve vs TAVR with a self-
expanding CoreValve were analyzed by an Echo Core Lab blinded toTable. Echocardiographic Parameters by Treatment Over Time
Baseline Discharge
TAVR SAVR TAVR SAVR TA
LVEDD (cm) 4.97  0.63 (347) 5.01  0.64 (311) 4.91  0.64 (303) 4.81  0.65 (225) 4.99  0
IVST (mm) 11.97  2.35 (341) 12.00  2.07 (309) 12.26  2.41 (295) 11.99  1.94 (219) 11.79  2
PWT (mm) 11.19  1.98 (338) 11.24  1.95 (311) 11.39  2.05 (297) 11.45  1.73 (216) 11.05  1
SV by 2DE (mL) 70.42  27.21 (185) 72.64  27.04 (171) 70.36  24.48 (168) 58.93  21.10 (122) 74.36  2
Doppler SV (mL) 75.77  23.49 (349) 74.96  20.16 (307) 74.89  19.90 (335) 63.35  19.71 (256) 77.93  2
LV mass (gm) 226.07  72.54 (333) 227.45  65.02 (304) 226.78  72.98 (291) 215.08  59.02 (212) 221.19  6
LV mass index (gm/m2) 122.45  35.73 (333) 123.54  33.55 (304) 122.82  35.97 (291) 116.43  28.94 (212) 119.45  3
 Moderate AR (%) 5.2% (20/385) 6.1% (21/346) 9.1% (33/363) 1.0% (3/306) 10.0% (treatment and outcomes. Echocardiography measurements including
AV gradient were performed according to established guidelines and
LV mass was calculated using the formula of Devereaux et al: 0.83 x
([(LVEDD þ LVPWT þ IVS)3 – [(LVEDD)3]) þ0.6. LVEDD¼LV end-dia-
stolic dimension, PWT¼posterior wall thickness, and
IVST¼interventricular septal thickness.
RESULTS Echo data were available in 389 TAVR and 353 SAVR pa-
tients (Table). LVEDD, PWT, IVS, LV mass, and SV were similar in
TAVR and SAVR at baseline. These variables were unchanged at
discharge with TAVR. However, after SAVR at discharge, LV mass
decreased from 227.4565.02 to 215.0859.02 gm (P¼0.002), and
LVEDD from 5.010.64 to 4.810.65 cm (P<0.0001), although PWT
and IVS were unchanged. 2D derived stroke volume (SV) also declined
at discharge from 72.6427.04 mL to 58.9321.10 mL (P¼0.01) after
SAVR, but not after TAVR (70.4227.21 mL to 70.3624.48 mL;
P¼0.46). Similar changes were observed with Doppler derived SV. At 1
year, LV mass, SV and LVEDD remained smaller following SAVR vs.
TAVR, a difference that persisted after exclusion of those with 
moderate aortic regurgitation (AR).
CONCLUSIONS Greater LV mass regression after SAVR is due to
smaller post-operative LVEDD associated with lower SV after SAVR
than TAVR. Further study is needed to identify the reasons for
reduced SV after SAVR.
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BACKGROUND This is the ﬁrst study comparing outcomes after
transfemoral transcatheter aortic valve replacement (TAVR) with
Symetis ACURATE (ACT) - a new device -, Medtronic CoreValve (MCV)
and Edwards Sapien XT (SXT).
METHODS We prospectively evaluated patients with severe aortic
stenosis undergoing transfemoral TAVR at two centers coordinated by
the same Heart Team. Study objectives were echocardiography ﬁnd-
ings and Valve Academic Research Consortium (VARC) at 30 days.
RESULTS We evaluated 162 patients (ACT n¼48, MCV n¼57, SXT
n¼57). Baseline clinical and imaging features are resumed in Table 1.
Immediately after the procedure, Device Success were lower with
MCV (97.9% vs 86% vs 94.7%; p¼0,049), as well as Aortic Valve Area
(1.900.26 vs 1.810.32 vs 2.010.28; p¼0.002), with no differences in
Mean Gradient (p¼0.752) or Moderate/Severe Aortic Regurgitation
(p¼0.272). At 30 days, there were no signiﬁcant difference in all-cause
mortality (p¼0.298), cardiovascular mortality (p¼0.222), myocardial
infarction (p¼0.776) and stroke (p¼0.999). Additionally, no differ-
ences were found in major vascular complications (p¼0.594), life-
threatening bleeding (0.378) and stage 3 acute kidney injury1 Month 6 Months 1 Year
VR SAVR TAVR SAVR TAVR SAVR
.65 (318) 4.74  0.66 (247) 5.01  0.67 (279) 4.74  0.63 (206) 4.98  0.66 (262) 4.80  0.56 (190)
.12 (312) 11.68  2.09 (245) 11.50  2.32 (269) 11.62  1.97 (205) 11.35  2.17 (257) 11.48  2.37 (189)
.83 (307) 10.96  1.79 (237) 10.57  1.82 (266) 11.12  1.87 (199) 10.51  1.89 (255) 10.21  1.96 (189)
4.59 (173) 59.76  20.71 (123) 72.37  22.04 (141) 66.34  22.74 (100) 73.45  23.81 (118) 71.45  22.01 (81)
3.53 (349) 67.59  20.29 (282) 79.69  23.33 (297) 73.57  20.35 (224) 79.56  22.90 (278) 74.78  21.35 (206)
9.63 (303) 200.22  58.38 (232) 213.07  65.74 (260) 201.79  57.83 (196) 207.83  64.02 (247) 192.71  58.54 (185)
3.88 (303) 108.83  29.31 (232) 114.23  30.74 (260) 108.67  26.81 (196) 111.35  29.85 (247) 102.80  27.99 (185)
36/359) 1.3% (4/308) 11.3% (36/318) 1.6% (4/252) 7.1% (21/297) 1.3% (3/223)
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with MCV (16.7% vs 38.6% vs 26.3%; p¼0.042), mainly due to a higher
need for permanent pacemakers (6.3% vs 24.6% vs 10.5%; p¼0.019).
After multivariate analysis MCV remained predictor of VARC com-
bined early safety endpoints.General
n[162ACCURATE
n[48CoreValve
n[57SAPIEN XT
n[57 pAge (y) 82.636.55 82.295.33 82.397.72 83.146.32 0.75
Male (n) 45.7% (74) 45.8% (22) 45.6% (26) 45.6% (26) 1BMI (Kg/m2) 26.964.33 28.393.93 25.604.13 27.114.49 0.001
Hypertension (n) 83.1% (133) 85.4% (41) 76.8% (43) 87.5% (49) 0.28Diabetes (n) 34.4% (55) 33.3% (16) 32.1% (18) 37.5% (21) 0.823COPD (n) 11.9% (19) 21.3% (10) 7.1% (4) 8.9% (5) 0.073Coronary Artery
Disease > 50% (n)51.9% (83) 47.9% (23) 53.6% (30) 53.6% (30) 0.806Creattinine
Clearance < 60mL/
min (n)71.7% (114) 68.8% (33) 81.8% (45) 64.3% (36) 0.105NYHA Functional Class
III/IV (n)74.7% (118) 89.6% (43) 69.6% (39) 66.7% (36) 0.016EUROSCORE II 7.596.42 6.534.5 8.296.66 7.857.49 0.41
STS PROM 6.033.7 6.072.81 5.453.08 6.634.82 0.441
Left Ventricle Ejection
Fraction (%)57.4113.15 58.6610.79 57.0214.4 56.7213.8 0.998Mean Aortic Valve
Gradient (mmHg)52.8414.92 50.9113.01 53.2615.90 54.0415.50 0.575Aortic Valve Area
(cm2)0.690.15 0.730.16 0.670.14 0.670.14 0.105CONCLUSIONS Although the three devices have shown good device
success rates and hemodynamic improvement on echocardiogram,
CoreValve use lead to higher combined early safety endpoints, mainly
because of more permanent pacemaker usage. Larger cohorts or ran-
domized trials are needed do corroborate these ﬁndings.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS TAVI, TAVR, Transfemoral aortic valve replacement
TCT-629
Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients
with Severe Aortic Stenosis and Mild Aortic Valve Calciﬁcation
Yigal Abramowitz,1 Hasan Jilaihawi,1 Tarun Chakravarty,1
Mohammad Kashif,1 Yoshio Kazuno,1 Yoshio Maeno,1
Nobuyuki Takahashi,1 Hiroyuki Kawamori,1 Rahul P. Sharma,1
Justin Cox,1 Wen Cheng,1 Raj Makkar1
1Cedars-Sinai Medical Center, Los-Angeles, CA
BACKGROUND Increased aortic valve calciﬁcation has been shown to
be associated with perivalvular regurgitation (PVR) post TAVR.
Nonetheless, there is limited data on the impact of extremely low
aortic valve calciﬁcation on the acute success of balloon-expandable
TAVR.
METHODS We studied patients with severe aortic stenosis that un-
derwent balloon-expandable TAVR and had a pre-procedural non-
contrast CT. Patients that had an aortic valve calciﬁcation score
(AVCS) of less than 1500 Agatston units (AU) were compared to pa-
tients with higher calciﬁcation scores.
RESULTS Seventy-four patients had low AVCS compared to 489 with
higher AVCS (mean Agatston score: 1049305 vs. 39892020). Pa-
tients with mild aortic valve calciﬁcation were younger (80.38 vs.
82.98.1; p¼0.01), had higher body mass index (29.17.4 vs. 26.85.8;
p¼0.01) and had female predominance (70.3% vs. 32.1%; p<0.001),
compared to patients with higher calciﬁcation scores. Pre-TAVR, pa-
tients with aortic valve calciﬁcation score 1500 had lower mean
aortic valve pressure gradient and less stenotic aortic valves
(37.39.8mmHg vs. 46.813.4mmHG; p<0.001 and 0.670.13cm2 vs.
0.630.15cm2; p¼0.02). Device success was 100% in the low calciﬁ-
cation group compared to 95.9% in patients with higher AVCS
(p¼0.076). Postdilatation and 2nd valve implantation was done in
8.8% and 0% compared to 9.5% and 3.7%, respectively (p¼0.85 and
0.09). Postprocedural PVR in the mild aortic valve calciﬁcation group
was lower (mild or more PVR: 13.5% vs. 25.9%; p¼0.023).There was nocase of valve embolization in the mild AVCS group. Thirty-day mor-
tality and major complications were similar between groups (Table).
One year mortality was 13.2% vs. 16.4% in the AVCS1500 vs.
AVCS>1500, respectively (p¼0.61).
Table. Procedural details and 30-days clinical outcomeAVCS £ 1500 Agatston
units
(n[74)AVCS > 1500 Agatston
units
(n[489) p-valueProcedural details:Device success 74 (100) 469 (95.9) 0.072nd valve 0 (0) 18 (3.7) 0.09Postdilatation 7 (9.5) 43 (8.8) 0.85Perivalvular leak: 0.02None / trace 64 (86.5) 358 (74.1)Mild 10 (13.5) 111 (23)Moderate 0 (0) 13 (2.7)Severe 0 (0) 1 (0.2)Valve embolization 0 (0) 3 (0.6) 0.530-days outcome:Mortality 1 (1.4) 13 (2.1) 0.5CVA/TIA 1 (1.4) 14 (2.9) 0.45Major bleeding 3 (4.1) 19 (3.9) 0.94Major vascular 4 (5.4) 13 (2.7) 0.2New permanent
pacemaker3 (4.9) 40 (10.1) 0.2Values are n (%).
CONCLUSIONS Balloon-expandable TAVR can be performed safely in
patients with extremely low AVCS. We demonstrated excellent acute
procedural outcome, lower rates of postprocedural PVR and no case of
valve embolization.
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BACKGROUND In patients with severe aortic stenosis undergoing
transfemoral aortic valve implantation (TAVI) device success was
signiﬁcantly higher with the balloon-expandable Edwards XT valve
(EXT) compared with the self-expanding CoreValve (CV) in the ran-
domized CHOICE trial. The second generation Edwards Sapien 3 valve
was designed to reduce paravalvular aortic regurgitation. Absence of
post-procedural aortic regurgitation was associated with a lower acute
and long-term mortality in the Partner trial. We compared the
outcome of the ES3 with the CoreValve in patients undergoing TAVI.
METHODS The ﬁrst 100 consecutive patients treated with the ES3
were compared with the last 100 consecutive patients treated with the
CoreValve (Clinical Trial Registration: NCT02162069). Mean STS-Score
was 10.27.9%. Post-procedural aortic regurgitation, rate of perma-
nent pacemaker implantation, and device success were analyzed ac-
cording to VARC criteria. Device size was based on multislice
computer tomography performed with a 256 Philips Brilliance iCT
scanner. Measurements of aortic annulus, left ventricular outﬂow
tract (LVOT) were performed with a dedicated software (3mensio
Structural Heart, version 7.0).
RESULTS Baseline characteristics were mostly similar between the
CoreValve and ES3 population: age 816 vs. 826 years (p¼0.24),
female 49% vs. 52% (p¼0.67), diabetes mellitus 34% vs. 38% (p¼0.56),
coronary artery disease 61% vs. 60% (p¼0.89), history of cardiac
surgery 14% vs. 9% (p¼0.27), pulmonary disease 36% vs. 60%
(p<0.01). Also the computer tomography acquired parameters did not
differ signiﬁcantly between the EXT and ES3 population. Post dilation
was necessary in 11% after CoreValve implantation and in no patient
after ES3 implantation (p<0.01). Rate of device success according to
